Low Molecular Weight Fucoidan Against Renal Ischemia-Reperfusion Injury Via Inhibition of the Mapk Signaling Pathway

Jihui Chen,Weiling Wang,Quanbin Zhang,Fei Li,Tianluo Lei,Dali Luo,Hong Zhou,Baoxue Yang
DOI: https://doi.org/10.1371/journal.pone.0056224
IF: 3.7
2013-01-01
PLoS ONE
Abstract:Ischemia reperfusion injury (IRI) is a leading cause of acute kidney injury (AKI) in both native and transplanted kidneys. As a common pathophysilological cause of acute renal failure (ARF), IRI‐induced AKI occurs in many clinical settings including renal transplantation, shock, and vascular surgery. The objective of the present study was to evaluate whether low‐molecular‐weight fucoidan (LMWF) could attenuate renal IRI in an animal model and in vitro cell models and study the mechanisms in which LMWF protects from IRI. Male mice were subjected to right renal ischemia for 30 min and reperfusion for 24 h, or to a sham operation with left kidney removed. Kidneys undergone IR showed characteristic morphological changes, such as tubular dilatation, and brush border loss. However, LMWF significantly corrected the renal dysfunction and the abnormal levels of MPO, MDA and SOD induced by IR. LMWF also inhibited the activation of MAPK pathways, which consequently resulted in a significant decrease in the expression of cyto‐c, ratios of Bax/Bcl‐2 and cleaved caspase‐3/caspase‐3, and phosphorylation of p53. LMWF alleviated hypoxia‐reoxygenation or CoCl2 induced cell viability loss and ΔΨm dissipation in HK2 renal tubular epithelial cells, which indicates LMWF may result in an inhibition of the apoptosis pathway through reducing activity of MAPK pathways in a dose‐dependent manner. Our findings show LMWF ameliorates acute renal IRI via inhibiting MAPK signaling pathways in vivo and in vitro. This protective effect is attributed to the improvement of renal function, balance of oxidative stress and antioxidative defense and anti‐apoptosis. In summary. the results suggest that LMWF may serve as a potential therapeutic agent for acute renal IRI, and MAPK pathways, especially JNK/p38‐MAPK is an appealing therapeutic target for AKI.
What problem does this paper attempt to address?